Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vitamin D binding protein macrophage-activating factor - Efranat

Drug Profile

Vitamin D binding protein macrophage-activating factor - Efranat

Alternative Names: EF-022; GcMAF; Globulin component macrophage activating factor

Latest Information Update: 28 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Einstein Medical Center
  • Developer Efranat; Socrates Institute for Therapeutic Immunology
  • Class Antineoplastics; Carrier proteins; Lymphokines
  • Mechanism of Action Macrophage activating factor replacements; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Recurrent respiratory papillomatosis; Solid tumours
  • Discontinued Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for preclinical development in Recurrent-respiratory-papillomatosis in Israel (Parenteral)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Recurrent) in Israel (IM, Injection)
  • 11 Dec 2017 Phase I development for Solid tumours is ongoing in Israel (Efranat pipeline, December 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top